Andexanet vs prothrombin concentrate complex for intracranial hemorrhage (ANNEXA-I trial)
The drug slowed hematoma expansion, but caused clots; patient-centered outcomes weren't seriously tested.
A randomized trial shows that andexanet can stem the progression of intracranial hemorrhage better than 4-factor prothrombin complex concentrate in patients taking factor Xa inhibitors. The clinical relevance is unclear, though, as patient-centered outcomes were not improved, and andexanet resulted in more serious thrombotic events than PCC.
Factor Xa in…
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.